PCSA Stock: Processa Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live pcsa stock price $6.68, comprehensive Processa Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time pcsa stock data and investment insights.
Loading chart...
Company Overview
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Company Information
- CEO
- George K. Ng
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
Contact Information
- Address
- 7380 Coca Cola Drive
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
Business Model & Strategy
Processa Pharmaceuticals, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO George K. Ng, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Processa Pharmaceuticals, Inc. competes in the Biotechnology within the broader Healthcare. With 15.1 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Capital Market, Processa Pharmaceuticals, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Processa Pharmaceuticals, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Processa Pharmaceuticals, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Processa Pharmaceuticals, Inc.
- ⚠Investors should consider how Processa Pharmaceuticals, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
15.14M
P/E Ratio
-5.81
Beta
1.09
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 15.14M market capitalization
- Trading Volume: 39.06M shares traded today
- Price Range: 52-week range of $0.11 - $8.88
- Exchange: Listed on NASDAQ Capital Market
Financial Metrics
Market Analysis for Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals, Inc. (PCSA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 15.14M, the company represents a significant player in its market. The stock is currently trading at $6.68 with a positivedaily change of 122.30%.
The company's 10 employee base and presence on the NASDAQ Capital Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -5.81, beta of 1.09, and 52-week price range from $0.11 to $8.88when evaluating investment opportunities.
Why Invest in Processa Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Capital Market)
- • Experienced leadership under George K. Ng
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.